Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HF-POLARIS trial of zenagamtide versus placebo in heart failure with preserved or mildly reduced ejection fraction and obesity
NL-OMON61065Phase 3Recruiting
- Sponsor
- Novo Nordisk
- Start
- May 2026
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF), heart failure with mid-range ejection fraction (HFmrEF) and obesity comparing Zenagamtide + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Primary composite heart failure endpoint. Started May 2026; status: recruiting.
02
Drugs
amycretin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)heart failure with mid-range ejection fraction (HFmrEF)obesity
Beyond the preview
Go deeper on NL-OMON61065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61065.